There's a new anthracycline being developed with no cardiotoxic effect seen in clinical trials. Poised to move into a pivotal phase 2b/3 in AML this year. Seems to be achieving a high number of CRs in heavily pre-treated patients.
https://moleculin.com/moleculin-announces-2023-year-end-annamycin-clinical-trials-preliminary-data-and-2024-expectations-for-multiple-data-readouts-and-transition-to-pivotal-phase-2b-3/
Cardioprotection thread, page-629
-
- There are more pages in this discussion • 278 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |